Neopterin and Oxidation Products in the Blood of Patients with Various Forms of Dementia

Pteridines

Volumn 14, Issue 3, 2003, Pages 88-93

  Frick, Barbara ^a   Neurauter, Gabriele ^a,b   Diez Ruiz, Antonio ^c   Schroecksnadel, Katharina ^a   Wirleitner, Barbara ^a   Leblhuber, Friedrich ^d   Fuchs, Dietmar ^a,b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF GRANADA   (Spain)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Dementia; Homocysteine; Neopterin; Oxidative stress; Peroxides

Indexed keywords

ANTIOXIDANT; GAMMA INTERFERON; HOMOCYSTEINE; NEOPTERIN; PEROXIDE; REACTIVE OXYGEN METABOLITE;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MONOCYTE; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0346150362     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2003.14.3.88     Document Type: Article

References (33)

1. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999; 19: 1721-1728.
2. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321: 89-92.
3. Oettl K, Wirleitner B, Baier-Bitterlich G, Grammer T, Fuchs D, Reibnegger G. Formation of oxygen radicals in solutions of 7,8-dihydroneopterin. Biochem Biophys Res Commun 1999; 264: 262-267.
4. Oettl K, Reibnegger G. Pteridine derivates as modulators of oxidative stress. Curr Drug Metab 2002; 3: 203-209.
5. Widner B, Baier-Bitterlich G, Wede I, Wirleitner B, Wachter H, Fuchs D. Neopterin derivatives modulate the nitration of tyrosine by peroxynitrite. Biochem Biophys Res Commun 1998; 248: 341-346.
6. Murr C, Fuchs D, Gössler W, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Esterbauer H, Wachter H. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994; 338: 223-226.
7. Herpfer I, Greilberger J, Ledinski G, Widner B, Fuchs D, Jurgens G. Neopterin and 7,8-dihydroneopterin interfere with low density lipoprotein oxidation mediated by peroxynitrite and/or cooper. Free Radical Res 2002; 36: 509-520.
8. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
9. Sattler W, Leblhuber F, Walli J, Widner B, Fuchs D. Cerebrospinal fluid levels of a-tocopherol and neopterin in patients with dementia. Pteridines 1999; 10: 220-224.
10. Solichova D, Melichar B, Svoboda I, Blaha V, Zadak Z. Fluorescence analysis of antioxidant vitamins and neopterin in nonagenarians. Biomed Chromatogr 1999; 13: 117-118.
11. Hronek M, Zadak Z, Solichova D, Jandik P, Melichar B. The association between specific nutritional antioxidants and manifestation of colorectal cancer. Nutrition 2000; 16: 189-191.
12. Versijpt J, Van Laere K, Dierckx RA, Dumont F, De Deyn PP, Slegers G, Korf J. Scintigraphic visualization of inflammation in neurodegenerative disorders. Nucl Med Commun 2003; 24: 209-221.
13. McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Mov Disord 1997; 12: 855-858.
14. Leblhuber F, Wall J, Demel U, Tilz GP, Widner B, Fuchs D. Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin Chem Lab Med 1999; 37: 429-431.
15. Leblhuber F, Walli J, Jellinger K, Tilz GP, Widner B, Laccone F, Fuchs D. Activated Immune system in patients with Huntington's disease. Clin Chem Lab Med 1998; 36: 747-750.
16. Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger R, Fuchs D. Hyperhomocysteinemia in dementia. J Neural Transm 2000; 107: 1469-1474.
17. Seshadri S, Beiser A, Selhub J, Jaques PF, Rosenberg IH, Dágostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
18. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm 2002; 109; 1445-1452.
19. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40: 225-227.
20. Frick B, Schröcksnadel K, Neurauter G, Wirleitner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003; 331: 19-23.
21. Perry G, Nunomura A, Cash AD, Taddeo MA, Hirai K, Aliev G, Avila J, Wataya T, Shimohama S, Atwood CS, Smith MA. Reactive oxygen: its sources and significance in Alzheimer disease. J Neural Transm Supp 2002; 62: 69-75.
22. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand 1989; 126: 23-33.
23. Olszewski AJ, McCully KS. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med 1993; 14: 683-693.
24. Reibnegger G, Huber LA, Jürgens G, Schönitzer D, Werner ER, Wachter H, Wick G, Traill KN. Approach to define "normal aging" in man. Immune function, serum lipids, lipoproteins and neopterin levels. Mech Ag Dev 1988; 46: 67-82.
25. Solichova D, Melichar B, Blaha V, Klejna M, Vavrova J, Palicka V, Zadak Z. Biochemical profile and survival in nonagenarians. Clin Biochem 2001; 34: 563-569.
26. McNerlan SE, Rea IM, Alexander HD. A whole blood method for measurement of intracellular TNF-α, INF-γ and IL -2 expression in stimulated CD3 + lymphocytes: differences between young and elderly subjects. Exp Gerontol 2002; 37: 227-234.
27. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinaemia due to oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Med 2001; 39: 691-694.
28. Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metabol 2002; 3: 225-232.
29. Laich A, Leblhuber F, Widner B, Artner-Dworzak E, Jellinger K, Fuchs D. Moderate hyperhomocysteinaemia in patients with Huntington's disease. Pteridines 2002; 13: 121-125.
30. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003; 134: 53-56.
31. Nathan CF, Murray HW, Wiebe ME, Rubin BY Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
32. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transmission 2000; 107: 343-353.
33. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-68.